{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:46:30Z","timestamp":1782510390409,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:24:21Z","timestamp":1779276261000},"page":"453-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surveillance Protocols"],"prefix":"10.1016","volume":"53","author":[{"given":"Heather","family":"Steckenrider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ucl.2026.03.009_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"AUA\/-SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.009_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)-a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.009_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.28397","article-title":"Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006","volume":"120","author":"Nielsen","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.009_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/BLC-211528","article-title":"Alternating cystoscopy with bladder EpiCheck\u00ae in the surveillance of low-grade intermediate-risk NMIBC: a cost comparison model","volume":"7","author":"Lotan","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ucl.2026.03.009_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s43058-025-00721-0","article-title":"Integration and evaluation of implementation strategies to improve guideline-concordant bladder cancer surveillance: a prospective observational study","volume":"6","author":"Zubkoff","year":"2025","journal-title":"Implement Sci Commun"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.009_bib6","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/cancers17101714","article-title":"Active surveillance in non-muscle invasive bladder cancer: a systematic review","volume":"17","author":"Campistol","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.009_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non\u2013muscle-invasive bladder cancer among older adults, 2004-2013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"Issue 6","key":"10.1016\/j.ucl.2026.03.009_bib8","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non\u2013muscle-invasive bladder cancer scoring system and substratification model proposed by the international bladder cancer group: a multicenter young academic urologists urothelial working group collaboration","volume":"7","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.009_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"10364","key":"10.1016\/j.ucl.2026.03.009_bib11","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.009_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.ucl.2026.03.009_bib13","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis","volume":"30","author":"\u015alusarczyk","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.009_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.15209","article-title":"Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification","volume":"127","author":"Kohada","year":"2021","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.009_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JU.0000000000001689","article-title":"Surveillance intensity in intermediate risk, nonmuscle invasive bladder cancer: revisiting the optimal timing and frequency of cystoscopy","volume":"206","author":"Bhat","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.009_bib16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.euo.2025.04.010","article-title":"Towards defining Follow-up strategies for patients with primary intermediate-risk non\u2013muscle-invasive bladder cancer","volume":"8","author":"Contieri","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.009_bib17","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.euo.2025.08.003","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: recommendations for definitions, risk stratification, management strategies, and clinical trial design from the international bladder cancer group","volume":"8","author":"Li","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.009_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/BLC-220055","article-title":"Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models","volume":"8","author":"Guerrero-Ramos","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ucl.2026.03.009_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European association of urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus calmette-guerin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.03.009_bib20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO\/and WHO classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.009_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.47391\/JPMA.20055","article-title":"Blue light cystoscopy- as an improvised diagnostic modality for bladder tumours","volume":"75","author":"Mushtaq","year":"2025","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.ucl.2026.03.009_bib22","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.03.009_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-160060","article-title":"Systematic review and meta-analysis on the impact of Hexaminolevulinate-Versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer","volume":"2","author":"Gakis","year":"2016","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.009_bib24","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"issue":"40","key":"10.1016\/j.ucl.2026.03.009_bib25","first-page":"1","article-title":"Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT","volume":"26","author":"Heer","year":"2025","journal-title":"Randomized Controlled Trial Health Technol Assess"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.009_bib26","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.urolonc.2023.01.009","article-title":"Cxbladder monitor testing to reduce cystoscopy frequency in patients with bladder cancer","volume":"41","author":"Li","year":"2023","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.009_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JU.0000000000004335","article-title":"Uromonitor: clinical validation and performance assessment of a urinary biomarker within the surveillance of patients with nonmuscle-invasive bladder cancer","volume":"213","author":"Ramos","year":"2025","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.009_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","article-title":"Urine biomarkers in bladder cancer \u2014 current status and future perspectives","volume":"20","author":"Maas","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.009_bib29","doi-asserted-by":"crossref","first-page":"796.e1","DOI":"10.1016\/j.urolonc.2020.04.026","article-title":"Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among society of urologic oncology (SUO) members","volume":"38","author":"Matulay","year":"2020","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.009_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.009_bib31","article-title":"Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy","volume":"40","author":"Baack Kukreja","year":"2022","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.009_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3442","article-title":"Extent of risk-aligned surveillance for cancer recurrence among patients with early-stage bladder cancer","volume":"1","author":"Schroeck","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.009_bib33","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1002\/bco2.468","article-title":"A novel bladder cancer surveillance schedule using bladder CX for patients on annual surveillance","volume":"6","author":"Guduguntla","year":"2025","journal-title":"BJUI Compass"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.009_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","article-title":"Use of the xpert bladder cancer monitor urinary biomarker test for guiding cystoscopy in high-grade non\u2013muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 trial","volume":"88","author":"Dreyer","year":"2025","journal-title":"Eur Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:55:43Z","timestamp":1782507343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000352"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance Protocols","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}